IBD: Body mass index does not affect the efficacy of ustha monoantigen resistance in Crohn's disease.

Crohn's disease is an unexplained inflammatory intestinal disease that can occur anywhere in the gastrointestinal tract, but occurs in the end of the rectum and the right half of the colon.
clinical manifestations of abdominal pain, diarrhea, intestinal obstruction, accompanied by fever, nutritional disorders and other extraintestinal manifestations.
long-term delay, repeated seizures, not easy to cure.
there is no cure, many patients have complications, need surgery, and the recurrence rate after surgery is very high.
the recurrence rate of the disease is related to the range of lesions, the strength of the disease attack, the extension of the course of the disease, the increase of age and other factors, the mortality rate also increased.
obesity is becoming more and more common all over the world.
More than 35 percent of adults in the U.S. are obese, and obesity is associated with an increased risk of immuno-mediated diseases such as rheumatoid arthritis and CD, as well as poor prognostising of CD and higher rates of surgery and hospitalization.
currently gaining more and more recognition in the treatment of Crohn's disease, but it is not clear whether weight has an effect on it.
study is intended to be conducted.
researchers followed up for a long time with all CD patients who used using using using using using using using using using usanu monoantigen, and the main endpoint of the study was clinical remission (CR), which divided the patients into subgroups based on the BMI selected for the study: weight-lt;18.5 kg/m2, normal 18.5 to 25 kg/m2, overweight 25 to slt;30 kg/m2, obesity of 30 kg/m2.
multi-regression analysis assessed the possible link between BMI and CR and corticosteroid-free CR results, and adjusted the important variables found in single-factor analysis.
study concluded that there were 254 CD patients receiving usano monotherapy.
in the 44th week of treatment, BMI was underweight at 67.9 percent (19 out of 28 patients), normally 51.3 percent (60 out of 117), overweight at 45.1 percent (32 out of 71), and their CR rates were no different.
the covariance, the multi-logic analysis found that BMI is an important predictor of CR.
significantly lower levels of usanu monoantidd drugs (2.98 mcg/mL; quarter-bit spacing, 2.86) in obese patients at week 44 compared to those who were overweight (4.84 mcg/mL; IQR, 3.51; P - 0.021) or obese.
(4.43mcg/m) for underweight or normal BMI; IQR, 2.82; P -0.014).
the study concluded that although BMI affects the level of the drug usano monoantigen, BMI has no effect on clinical efficacy.
.